Tabbara I A
Bone Marrow Transplant Program, George Washington University School of Medicine, Washington, DC 20037, USA.
South Med J. 1996 Sep;89(9):857-68. doi: 10.1097/00007611-199609000-00003.
Allogeneic bone marrow transplantation (BMT) after high-dose, marrow-ablative chemoradiotherapy has been established as the treatment of choice for various hematologic, neoplastic, and congenital disorders. The most common type of marrow graft is an allogeneic one from a sibling donor who has compatible human leukocyte antigen (HLA). Only 30% of patients requiring allogeneic BMT have an HLA-compatible sibling donor. Over the past few years, marrows from unrelated HLA-compatible donors have been used with increasing frequency and promising outcome in certain hematologic malignancies. Despite the morbidity and mortality associated with this treatment modality, allogeneic BMT may provide a 20% to 90% chance of long-term, disease-free survival to patients with a wide variety of neoplastic and abnormal marrow disorders.
大剂量、清髓性放化疗后的异基因骨髓移植（BMT）已被确立为各种血液系统疾病、肿瘤性疾病和先天性疾病的首选治疗方法。最常见的骨髓移植类型是来自具有相容人类白细胞抗原（HLA）的同胞供体的异基因移植。仅30%需要异基因BMT的患者有HLA相容的同胞供体。在过去几年中，来自无关HLA相容供体的骨髓在某些血液系统恶性肿瘤中的使用频率越来越高，且疗效良好。尽管这种治疗方式存在发病率和死亡率，但异基因BMT可为患有各种肿瘤性和异常骨髓疾病的患者提供20%至90%的长期无病生存机会。
